CRISPR Therapeutics AG (CRSP) Net Income (2016 - 2025)
Historic Net Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$106.4 million.
- CRISPR Therapeutics AG's Net Income fell 2381.76% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$530.0 million, marking a year-over-year decrease of 9603.28%. This contributed to the annual value of -$408.0 million for FY2024, which is 12125.16% down from last year.
- CRISPR Therapeutics AG's Net Income amounted to -$106.4 million in Q3 2025, which was down 2381.76% from -$208.6 million recorded in Q2 2025.
- CRISPR Therapeutics AG's Net Income's 5-year high stood at $759.2 million during Q2 2021, with a 5-year trough of -$208.6 million in Q2 2025.
- In the last 5 years, CRISPR Therapeutics AG's Net Income had a median value of -$113.2 million in 2021 and averaged -$69.4 million.
- In the last 5 years, CRISPR Therapeutics AG's Net Income soared by 105287.85% in 2021 and then tumbled by 23481.09% in 2024.
- Quarter analysis of 5 years shows CRISPR Therapeutics AG's Net Income stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then plummeted by 34.71% to -$106.4 million in 2025.
- Its Net Income was -$106.4 million in Q3 2025, compared to -$208.6 million in Q2 2025 and -$136.0 million in Q1 2025.